BIOLINERX     Print Page  Close Window

SEC filings
F-1
BIOLINERX LTD. filed this Form F-1 on 10/02/2012
Entire Document
 
44

 
 
We expect our revenues for the next several years to be derived primarily from payments under our current agreement with Ikaria, as well as additional collaborations that we may enter into in the future, including with regard to BL-1020, BL-5010, BL-7040, BL-8040, BL-1021 or other therapeutic candidates. Furthermore, we may receive future royalties on product sales, if any, under our agreement with Ikaria, as well as under any future agreement relating to BL-1020, BL-5010, BL-7040, BL-8040, BL-1021 or other compounds.
 
            Our remaining therapeutic candidates are currently in development and, therefore, we do not expect to generate any revenues from these products for at least the next several years, if at all.
 
Research and Development
 
Our research and development expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory supplies and costs for facilities and equipment. We primarily use external service providers to manufacture our product candidates for clinical trials and for the majority of our preclinical and clinical development work. We charge all research and development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop our therapeutic candidates.
 
The following table identifies our current major research and development projects:
 
Project
 
Status
 
Expected or Recent Near Term Milestone
         
BL-1020
 
Phase 2/3 CLARITY trial
 
CLARITY study results- second half of 2013
         
BL-1040
 
CE registration pivotal trial
 
PRESERVATION 1 study results – first half of 2014
         
BL-5010
 
Completed phase 1/2
 
Completion of unique applicator prototype by end of 2012; commencement of pivotal CE Mark registration trial in first half of 2013
         
BL-7040
 
Phase 2a trial
 
Study results - end of 2012/early 2013
         
BL-8040
 
Completed phase 1/2
 
Phase 2 expected to commence during the first half of 2013
         
BL-1021
 
Completed phase 1a
 
Phase 1b multiple ascending dose study